Lynx1 Capital Management LP
An institutional investment manager in DORADO, PR. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 13, 2026. SEC CIK 1910456.
- Reported value$865.5m
- Positions27
Holdings: 27 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| GH Research plc | ORDINARY SHARES | G3855L106 | 357 | 41.2% | 13,263,288 | Added+2,500,000 | |
| Cullinan Therapeutics IncCGEM | COM | 230031106 | 163 | 18.9% | 8,963,500 | Unchanged | |
| Stoke Therapeutics IncSTOK | COM | 86150R107 | 132 | 15.3% | 4,038,404 | Reduced−725,269 | |
| Agios Pharmaceuticals IncAGIO | COM | 00847X104 | 127 | 14.6% | 3,408,937 | Added+797,369 | |
| C4 Therapeutics IncCCCC | COM STK | 12529R107 | 34.2 | 4.0% | 7,326,691 | Added+327,789 | |
| Korro Bio IncKRRO | COM | 500946108 | 20.3 | 2.3% | 1,538,296 | Unchanged | |
| Tscan Therapeutics IncTCRX | COM | 89854M101 | 7.9 | 0.9% | 8,019,148 | Unchanged | |
| Precision Biosciences IncDTIL | COM NEW | 74019P207 | 7.5 | 0.9% | 950,466 | Reduced−34,647 | |
| Neuphoria Therapeutics IncNEUP | COM | 64136E102 | 3.8 | 0.4% | 875,328 | Unchanged | |
| Passage Bio IncPASG | COM NEW | 702712209 | 3.3 | 0.4% | 673,759 | Added+50,055 | |
| CG Oncology IncCGON | COM | 156944100 | 2.2 | 0.3% | 31,391 | Reduced−200 | |
| Pliant Therapeutics IncPLRX | COM | 729139105 | 2.0 | 0.2% | 1,798,070 | New+1,798,070 | |
| Entrada Therapeutics IncTRDA | COM | 29384C108 | 1.3 | 0.2% | 178,606 | Reduced−33,083 | |
| Vyne Therapeutics Inc | COM | 92941V308 | 1.1 | 0.1% | 1,628,700 | Unchanged | |
| Proqr Thrapeutics N V | SHS EURO | N71542109 | 1.0 | 0.1% | 521,413 | Added+452,927 | |
| Traws Pharma IncTRAW | COM NEW | 68232V884 | 0.5 | <0.1% | 559,470 | Added+544,392 | |
| Foghorn Therapeutics IncFHTX | COM | 344174107 | 0.3 | <0.1% | 61,588 | New+61,588 | |
| Denali Therapeutics IncDNLI | COM | 24823R105 | 0.3 | <0.1% | 11,658 | Reduced−1,868,645 | |
| Xencor IncXNCR | COM | 98401F105 | 0.3 | <0.1% | 18,194 | Reduced−518,204 | |
| Absci CorporationABSI | COM | 00091E109 | 0.2 | <0.1% | 21,245 | Unchanged | |
| Werewolf Therapeutics IncHOWL | COM | 95075A107 | 0.2 | <0.1% | 657,786 | Unchanged | |
| Immatics N.V | SHS | N44445109 | 0.2 | <0.1% | 23,236 | Reduced−193,737 | |
| Avalo Therapeutics IncAVTX | COM NEW | 05338F306 | 0.2 | <0.1% | 10,100 | New+10,100 | |
| Bolt Biotherapeutics IncBOLT | COM NEW | 097702203 | 0.1 | <0.1% | 30,800 | Unchanged | |
| Nuvation Bio IncNUVB | COM CL A | 67080N101 | 0.1 | <0.1% | 16,029 | New+16,029 | |
| Eupraxia Pharmaceuticals IncEPRX | COM | 29842P105 | 0.1 | <0.1% | 10,000 | New+10,000 | |
| Inhibikase Therapeutics IncIKT | COM NEW | 45719W205 | 0.0 | <0.1% | 20,000 | New+20,000 |
Sold out: 2 positions
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Design Therapeutics IncDSGN | COM | 25056L103 | 0.0 | 0.0% | 0 | Sold out−119,516 | |
| Ibio IncIBIO | COM NEW | 451033708 | 0.0 | 0.0% | 0 | Sold out−68,076 |
Source: SEC EDGAR, Form 13F-HR, accession 0001910456-26-000004 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.